Clinical Trial

Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The current study is being conducted to find an optimal Oral Paclitaxel + Encequidar dose and regimen based on prior experience with oral paclitaxel (stage 1) and to compare that dose to an accepted dose and regimen of intravenous (IV) paclitaxel in subjects with metastatic breast cancer (stage 2).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-14.
Trial Details
NCT Number NCT06835400
Lead Sponsor Health Hope Pharma
Conditions Metastatic Breast Cancer
Enrollment 340 participants
Start Date 2025-09
Primary Completion 2028-04 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2025-07-11